Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024
Integrated BioPharma (OTCQX:INBP) reported its financial results for the quarter and fiscal year ended June 30, 2024. Quarterly revenue was $12.7 million, a 2.3% decrease from $13.0 million in the same period in 2023. Quarterly operating income rose to $402,000 from $79,000. Fiscal year revenue was $50.3 million, down 0.7% from $50.7 million in 2023. Fiscal year operating income increased to $0.3 million from $0.1 million. Quarterly net income was $0.3 million or $0.01 per share, compared to $40,000 or $0.00 per share in the previous year. Fiscal year net income was $112,000 or $0.00 per share, versus a net loss of $34,000 or $0.00 per share last year. The company highlighted consistent revenue from its top two customers in the Contract Manufacturing Segment, representing 90% and 89% of total revenue in 2024 and 2023, respectively. The Co-CEOs expressed optimism about new prospects in contract manufacturing and warehousing and distribution.
Integrated BioPharma (OTCQX:INBP) ha riportato i risultati finanziari per il trimestre e l'anno fiscale conclusosi il 30 giugno 2024. I ricavi trimestrali sono stati di 12,7 milioni di dollari, registrando un decremento del 2,3% rispetto ai 13,0 milioni dello stesso periodo del 2023. L'utile operativo trimestrale è aumentato a 402.000 dollari, rispetto ai 79.000 dollari. I ricavi annuali hanno raggiunto i 50,3 milioni di dollari, in diminuzione dello 0,7% rispetto ai 50,7 milioni del 2023. L'utile operativo annuale è salito a 0,3 milioni di dollari da 0,1 milioni di dollari. Il reddito netto trimestrale è stato di 0,3 milioni di dollari o 0,01 dollari per azione, rispetto a 40.000 dollari o 0,00 dollari per azione dell'anno precedente. Il reddito netto annuale è stato di 112.000 dollari o 0,00 dollari per azione, rispetto a una perdita netta di 34.000 dollari o 0,00 dollari per azione dell'anno scorso. L'azienda ha evidenziato ricavi costanti dai suoi due principali clienti nel segmento della produzione su contratto, che rappresentano il 90% e l'89% dei ricavi totali nel 2024 e nel 2023, rispettivamente. I Co-CEOs hanno espresso ottimismo riguardo a nuove opportunità nella produzione su contratto e nella gestione e distribuzione.
Integrated BioPharma (OTCQX:INBP) informó sus resultados financieros para el trimestre y el año fiscal que terminó el 30 de junio de 2024. Los ingresos trimestrales fueron de 12,7 millones de dólares, una disminución del 2,3% en comparación con 13,0 millones de dólares en el mismo período de 2023. El ingreso operativo trimestral aumentó a 402.000 dólares desde 79.000 dólares. Los ingresos del año fiscal fueron de 50,3 millones de dólares, una caída del 0,7% en comparación con 50,7 millones de dólares en 2023. El ingreso operativo anual creció a 0,3 millones de dólares desde 0,1 millones de dólares. El ingreso neto trimestral fue de 0,3 millones de dólares o 0,01 dólares por acción, en comparación con 40.000 dólares o 0,00 dólares por acción del año anterior. El ingreso neto anual fue de 112.000 dólares o 0,00 dólares por acción, frente a una pérdida neta de 34.000 dólares o 0,00 dólares por acción el año pasado. La compañía destacó ingresos consistentes de sus dos principales clientes en el segmento de fabricación por contrato, representando el 90% y el 89% de los ingresos totales en 2024 y 2023, respectivamente. Los Co-CEOs expresaron optimismo sobre nuevas perspectivas en la fabricación por contrato y en el almacenamiento y distribución.
Integrated BioPharma (OTCQX:INBP)는 2024년 6월 30일 종료된 분기와 회계연도의 재무 결과를 발표했습니다. 분기 수익은 1,270만 달러로, 2023년 같은 기간에 비해 2.3% 감소했습니다. 분기 영업 이익은 79,000달러에서 402,000달러로 증가했습니다. 회계연도 수익은 5,030만 달러로, 2023년의 5,070만 달러에서 0.7% 감소했습니다. 회계연도 영업 이익은 10만 달러에서 30만 달러로 증가했습니다. 분기 순이익은 30만 달러, 즉 주당 0.01달러였으며, 지난해의 40,000달러 또는 주당 0.00달러와 비교됩니다. 회계연도 순이익은 11만 2,000달러 또는 주당 0.00달러였으며, 지난해의 34,000달러 또는 주당 0.00달러의 순손실에 비해 개선되었습니다. 회사는 계약 제조 부문에서 상위 두 고객으로부터의 꾸준한 수익을 강조했으며, 이는 각각 2024년과 2023년 총 수익의 90% 및 89%를 차지했습니다. 공동 CEO들은 계약 제조, 물류 및 유통 분야의 새로운 전망에 대해 낙관적인 의견을 밝혔습니다.
Integrated BioPharma (OTCQX:INBP) a rapporté ses résultats financiers pour le trimestre et l'année fiscale clos le 30 juin 2024. Les revenus trimestriels se sont élevés à 12,7 millions de dollars, soit une diminution de 2,3% par rapport à 13,0 millions de dollars au cours de la même période en 2023. Le bénéfice d'exploitation trimestriel a augmenté pour atteindre 402 000 dollars, contre 79 000 dollars. Les revenus annuels s'élevaient à 50,3 millions de dollars, soit une baisse de 0,7% par rapport à 50,7 millions de dollars en 2023. Le bénéfice d'exploitation annuel a augmenté à 0,3 million de dollars, contre 0,1 million de dollars. Le bénéfice net trimestriel était de 0,3 million de dollars ou 0,01 dollar par action, contre 40 000 dollars ou 0,00 dollar par action l'année précédente. Le bénéfice net annuel s'élevait à 112 000 dollars ou 0,00 dollar par action, contre une perte nette de 34 000 dollars ou 0,00 dollar par action l'année dernière. La société a souligné des revenus constants de ses deux principaux clients dans le secteur de la fabrication sous contrat, représentant 90% et 89% du revenu total en 2024 et 2023, respectivement. Les Co-CEO ont exprimé leur optimisme quant aux nouvelles perspectives dans la fabrication sous contrat et la gestion et distribution.
Integrated BioPharma (OTCQX:INBP) hat die finanziellen Ergebnisse für das am 30. Juni 2024 endende Quartal und Geschäftsjahr veröffentlicht. Der Quartalsumsatz betrug 12,7 Millionen Dollar, ein Rückgang von 2,3% im Vergleich zu 13,0 Millionen Dollar im gleichen Zeitraum 2023. Der Quartalsbetriebsergebnis stieg auf 402.000 Dollar von 79.000 Dollar. Der Jahresumsatz belief sich auf 50,3 Millionen Dollar, was einem Rückgang von 0,7% im Vergleich zu 50,7 Millionen Dollar im Jahr 2023 entspricht. Das Jahresbetriebsergebnis erhöhte sich auf 0,3 Millionen Dollar von 0,1 Millionen Dollar. Der Quartalsnettoertrag betrug 0,3 Millionen Dollar oder 0,01 Dollar pro Aktie, verglichen mit 40.000 Dollar oder 0,00 Dollar pro Aktie im Vorjahr. Der Jahresnettoertrag betrug 112.000 Dollar oder 0,00 Dollar pro Aktie, verglichen mit einem Nettoverlust von 34.000 Dollar oder 0,00 Dollar pro Aktie im letzten Jahr. Das Unternehmen hob die konstanten Einnahmen seiner beiden größten Kunden im Bereich der Vertragsfertigung hervor, die 2024 und 2023 jeweils 90% und 89% des Gesamtergebnisses ausmachten. Die Co-CEOs äußerten Optimismus bezüglich neuer Perspektiven in der Vertragsfertigung sowie in Lagerung und Distribution.
- Operating income for the quarter increased to $402,000 from $79,000.
- Fiscal year operating income rose to $0.3 million from $0.1 million.
- Quarterly net income increased to $0.3 million or $0.01 per share from $40,000 or $0.00 per share.
- Fiscal year net income was $112,000 compared to a net loss of $34,000.
- Quarterly revenue decreased by 2.3% to $12.7 million.
- Fiscal year revenue slightly declined by 0.7% to $50.3 million.
HILLSIDE, NJ / ACCESSWIRE / September 20, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2024.
Revenue for the quarter ended June 30, 2024 was
Revenues for the fiscal year ended June 30, 2024 were
For the quarter ended June 30, 2024, the Company had net income of approximately
For the fiscal year ended June 30, 2024, the Company had net income of approximately
"While our revenue decreased by less than
A summary of our financial results for the three months and fiscal years ended June 30, 2024 and 2023 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except share and per share amounts)
(unaudited)
| Three Months Ended |
|
| Fiscal Year Ended |
| |||||||||||
| June 30, |
|
| June 30, |
| |||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| |||||
|
|
|
|
|
|
|
|
|
|
|
| |||||
Total revenue |
| $ | 12,746 |
|
| $ | 12,994 |
|
| $ | 50,317 |
|
| $ | 50,672 |
|
Cost of sales |
|
| 11,462 |
|
|
| 12,008 |
|
|
| 46,433 |
|
|
| 46,611 |
|
Gross profit |
|
| 1,284 |
|
|
| 986 |
|
|
| 3,884 |
|
|
| 4,061 |
|
Selling and administrative expenses |
|
| 882 |
|
|
| 907 |
|
|
| 3,633 |
|
|
| 3,941 |
|
Operating income |
|
| 402 |
|
|
| 79 |
|
|
| 251 |
|
|
| 120 |
|
Other income (expense), net |
|
| 12 |
|
|
| 4 |
|
|
| 17 |
|
|
| (20 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Income before income taxes |
|
| 414 |
|
|
| 83 |
|
|
| 268 |
|
|
| 100 |
|
Income tax expense, net |
|
| 146 |
|
|
| 43 |
|
|
| 156 |
|
|
| 134 |
|
Net income (loss) |
| $ | 268 |
|
| $ | 40 |
|
| $ | 112 |
|
| $ | (34 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Net income (loss) per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
| $ | 0.01 |
|
| $ | 0.00 |
|
| $ | 0.00 |
|
| $ | (0.00 | ) |
Diluted |
| $ | 0.01 |
|
| $ | 0.00 |
|
| $ | 0.00 |
|
| $ | (0.00 | ) |
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
| 30,099,610 |
|
|
| 29,949,610 |
|
|
| 30,066,003 |
|
|
| 29,949,610 |
|
Diluted |
|
| 30,702,683 |
|
|
| 31,368,838 |
|
|
| 30,873,681 |
|
|
| 29,949,610 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation and the tightened labor markets; the impact of the war in Ukraine; the impact of the Israel-Hamas war; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on accesswire.com
FAQ
What were Integrated BioPharma's quarterly earnings for Q2 2024?
How did Integrated BioPharma's revenue perform in fiscal year 2024?
What is Integrated BioPharma's stock symbol?
How did Integrated BioPharma's operating income change in fiscal year 2024?
What was Integrated BioPharma's net income for fiscal year 2024?
